Probiotics  ||| S:0 E:11 ||| NNP
as  ||| S:11 E:14 ||| IN
functional  ||| S:14 E:25 ||| JJ
food  ||| S:25 E:30 ||| NN
products ||| S:30 E:38 ||| NNS
:  ||| S:38 E:40 ||| :
manufacture  ||| S:40 E:52 ||| NN
and  ||| S:52 E:56 ||| CC
approaches  ||| S:56 E:67 ||| NNS
to  ||| S:67 E:70 ||| TO
evaluating  ||| S:70 E:81 ||| VBG
of  ||| S:81 E:84 ||| IN
the  ||| S:84 E:88 ||| DT
effectiveness  ||| S:88 E:102 ||| NN
This  ||| S:102 E:107 ||| DT
review  ||| S:107 E:114 ||| NN
concerns  ||| S:114 E:123 ||| NNS
the  ||| S:123 E:127 ||| DT
issues  ||| S:127 E:134 ||| NNS
of  ||| S:134 E:137 ||| IN
foodfortifications  ||| S:137 E:156 ||| NN
and  ||| S:156 E:160 ||| CC
the  ||| S:160 E:164 ||| DT
creation  ||| S:164 E:173 ||| NN
of  ||| S:173 E:176 ||| IN
functional  ||| S:176 E:187 ||| JJ
foods  ||| S:187 E:193 ||| NNS
( ||| S:193 E:194 ||| -LRB-
FF ||| S:194 E:196 ||| NNP
)  ||| S:196 E:198 ||| -RRB-
and  ||| S:198 E:202 ||| CC
food  ||| S:202 E:207 ||| NN
supplements  ||| S:207 E:219 ||| VBZ
based  ||| S:219 E:225 ||| VBN
on  ||| S:225 E:228 ||| IN
probiotics  ||| S:228 E:239 ||| NN
and  ||| S:239 E:243 ||| CC
covers  ||| S:243 E:250 ||| VBZ
an  ||| S:250 E:253 ||| DT
issue  ||| S:253 E:259 ||| NN
of  ||| S:259 E:262 ||| IN
approaches  ||| S:262 E:273 ||| NNS
to  ||| S:273 E:276 ||| TO
the  ||| S:276 E:280 ||| DT
regulation  ||| S:280 E:291 ||| NN
of  ||| S:291 E:294 ||| IN
probiotic  ||| S:294 E:304 ||| JJ
food  ||| S:304 E:309 ||| NN
products  ||| S:309 E:318 ||| NNS
in  ||| S:318 E:321 ||| IN
various  ||| S:321 E:329 ||| JJ
countries ||| S:329 E:338 ||| NNS
.  ||| S:338 E:340 ||| .
The  ||| S:340 E:344 ||| DT
status  ||| S:344 E:351 ||| NN
of  ||| S:351 E:354 ||| IN
functional  ||| S:354 E:365 ||| JJ
foods ||| S:365 E:370 ||| NNS
,  ||| S:370 E:372 ||| ,
optimizing  ||| S:372 E:383 ||| JJ
GIT  ||| S:383 E:387 ||| NN
functions ||| S:387 E:396 ||| NNS
,  ||| S:396 E:398 ||| ,
as  ||| S:398 E:401 ||| IN
a  ||| S:401 E:403 ||| DT
separate  ||| S:403 E:412 ||| JJ
category  ||| S:412 E:421 ||| NN
of  ||| S:421 E:424 ||| IN
FF  ||| S:424 E:427 ||| NNP
is  ||| S:427 E:430 ||| VBZ
emphasized ||| S:430 E:440 ||| VBN
.  ||| S:440 E:442 ||| .
Considering  ||| S:442 E:454 ||| VBG
the  ||| S:454 E:458 ||| DT
strain-specificity  ||| S:458 E:477 ||| JJ
effect  ||| S:477 E:484 ||| NN
of  ||| S:484 E:487 ||| IN
probiotics ||| S:487 E:497 ||| NN
,  ||| S:497 E:499 ||| ,
the  ||| S:499 E:503 ||| DT
minimum  ||| S:503 E:511 ||| JJ
criteria  ||| S:511 E:520 ||| NNS
used  ||| S:520 E:525 ||| VBN
for  ||| S:525 E:529 ||| IN
probiotics  ||| S:529 E:540 ||| NN
in  ||| S:540 E:543 ||| IN
food  ||| S:543 E:548 ||| NN
products  ||| S:548 E:557 ||| NNS
are ||| S:557 E:560 ||| VBP
:  ||| S:560 E:562 ||| :
1 ||| S:562 E:563 ||| LS
)  ||| S:563 E:565 ||| -RRB-
the  ||| S:565 E:569 ||| DT
need  ||| S:569 E:574 ||| NN
to  ||| S:574 E:577 ||| TO
identify  ||| S:577 E:586 ||| VB
a  ||| S:586 E:588 ||| DT
probiotics  ||| S:588 E:599 ||| NN
at  ||| S:599 E:602 ||| IN
genus ||| S:602 E:607 ||| NN
,  ||| S:607 E:609 ||| ,
species ||| S:609 E:616 ||| NNS
,  ||| S:616 E:618 ||| ,
and  ||| S:618 E:622 ||| CC
strain  ||| S:622 E:629 ||| NN
levels ||| S:629 E:635 ||| NNS
,  ||| S:635 E:637 ||| ,
using  ||| S:637 E:643 ||| VBG
the  ||| S:643 E:647 ||| DT
high-resolution  ||| S:647 E:663 ||| JJ
techniques ||| S:663 E:673 ||| NNS
,  ||| S:673 E:675 ||| ,
2 ||| S:675 E:676 ||| LS
)  ||| S:676 E:678 ||| -RRB-
the  ||| S:678 E:682 ||| DT
viability  ||| S:682 E:692 ||| NN
and  ||| S:692 E:696 ||| CC
the  ||| S:696 E:700 ||| DT
presence  ||| S:700 E:709 ||| NN
of  ||| S:709 E:712 ||| IN
a  ||| S:712 E:714 ||| DT
sufficient  ||| S:714 E:725 ||| JJ
amount  ||| S:725 E:732 ||| NN
of  ||| S:732 E:735 ||| IN
the  ||| S:735 E:739 ||| DT
probiotic  ||| S:739 E:749 ||| NN
in  ||| S:749 E:752 ||| IN
product  ||| S:752 E:760 ||| NN
at  ||| S:760 E:763 ||| IN
the  ||| S:763 E:767 ||| DT
end  ||| S:767 E:771 ||| NN
of  ||| S:771 E:774 ||| IN
shelf  ||| S:774 E:780 ||| NN
life ||| S:780 E:784 ||| NN
,  ||| S:784 E:786 ||| ,
3 ||| S:786 E:787 ||| LS
)  ||| S:787 E:789 ||| -RRB-
the  ||| S:789 E:793 ||| DT
proof  ||| S:793 E:799 ||| NN
of  ||| S:799 E:802 ||| IN
functional  ||| S:802 E:813 ||| JJ
characteristics  ||| S:813 E:829 ||| NNS
inherent  ||| S:829 E:838 ||| JJ
to  ||| S:838 E:841 ||| TO
probiotic  ||| S:841 E:851 ||| VB
strains ||| S:851 E:858 ||| NNS
,  ||| S:858 E:860 ||| ,
in  ||| S:860 E:863 ||| IN
the  ||| S:863 E:867 ||| DT
controlled  ||| S:867 E:878 ||| JJ
experiments ||| S:878 E:889 ||| NNS
.  ||| S:889 E:891 ||| .
The  ||| S:891 E:895 ||| DT
recommended  ||| S:895 E:907 ||| VBN
by  ||| S:907 E:910 ||| IN
FA  ||| S:910 E:913 ||| NNP
O ||| S:913 E:914 ||| NNP
/ ||| S:914 E:915 ||| NNP
WHO  ||| S:915 E:919 ||| WP
three-stage  ||| S:919 E:931 ||| JJ
evaluation  ||| S:931 E:942 ||| NN
procedure  ||| S:942 E:952 ||| NN
offunctional  ||| S:952 E:965 ||| NN
efficiency  ||| S:965 E:976 ||| NN
of  ||| S:976 E:979 ||| IN
FF  ||| S:979 E:982 ||| NNP
includes ||| S:982 E:990 ||| VBZ
:  ||| S:990 E:992 ||| :
Phase  ||| S:992 E:998 ||| NNP
I--safety  ||| S:998 E:1008 ||| JJ
assessment  ||| S:1008 E:1019 ||| NN
in  ||| S:1019 E:1022 ||| IN
in  ||| S:1022 E:1025 ||| IN
vitro  ||| S:1025 E:1031 ||| NN
and  ||| S:1031 E:1035 ||| CC
in  ||| S:1035 E:1038 ||| IN
vivo  ||| S:1038 E:1043 ||| JJ
experiments ||| S:1043 E:1054 ||| NNS
,  ||| S:1054 E:1056 ||| ,
Phase  ||| S:1056 E:1062 ||| NNP
II--Evaluation  ||| S:1062 E:1077 ||| NNP
in  ||| S:1077 E:1080 ||| IN
the  ||| S:1080 E:1084 ||| DT
Double-Blind ||| S:1084 E:1096 ||| JJ
,  ||| S:1096 E:1098 ||| ,
Randomized ||| S:1098 E:1108 ||| NNP
,  ||| S:1108 E:1110 ||| ,
Placebo-Controlled  ||| S:1110 E:1129 ||| JJ
trial  ||| S:1129 E:1135 ||| NN
( ||| S:1135 E:1136 ||| -LRB-
DBRPC ||| S:1136 E:1141 ||| NNP
)  ||| S:1141 E:1143 ||| -RRB-
and  ||| S:1143 E:1147 ||| CC
Phase  ||| S:1147 E:1153 ||| NNP
III--Post-approval  ||| S:1153 E:1172 ||| JJ
monitoring ||| S:1172 E:1182 ||| NN
.  ||| S:1182 E:1184 ||| .
It  ||| S:1184 E:1187 ||| PRP
is  ||| S:1187 E:1190 ||| VBZ
noted  ||| S:1190 E:1196 ||| VBN
that  ||| S:1196 E:1201 ||| IN
along  ||| S:1201 E:1207 ||| RB
with  ||| S:1207 E:1212 ||| IN
the  ||| S:1212 E:1216 ||| DT
ability  ||| S:1216 E:1224 ||| NN
to  ||| S:1224 E:1227 ||| TO
obtain  ||| S:1227 E:1234 ||| VB
statistically  ||| S:1234 E:1248 ||| RB
significant  ||| S:1248 E:1260 ||| JJ
results  ||| S:1260 E:1268 ||| NNS
of  ||| S:1268 E:1271 ||| IN
the  ||| S:1271 E:1275 ||| DT
evaluation ||| S:1275 E:1285 ||| NN
,  ||| S:1285 E:1287 ||| ,
there  ||| S:1287 E:1293 ||| EX
are  ||| S:1293 E:1297 ||| VBP
practical  ||| S:1297 E:1307 ||| JJ
difficulties  ||| S:1307 E:1320 ||| NNS
of  ||| S:1320 E:1323 ||| IN
conducting  ||| S:1323 E:1334 ||| VBG
DBRPC  ||| S:1334 E:1340 ||| NNP
( ||| S:1340 E:1341 ||| -LRB-
duration ||| S:1341 E:1349 ||| NN
,  ||| S:1349 E:1351 ||| ,
costs ||| S:1351 E:1356 ||| NNS
,  ||| S:1356 E:1358 ||| ,
difficulties  ||| S:1358 E:1371 ||| NNS
in  ||| S:1371 E:1374 ||| IN
selection  ||| S:1374 E:1384 ||| NN
of  ||| S:1384 E:1387 ||| IN
target  ||| S:1387 E:1394 ||| NN
biomarkers  ||| S:1394 E:1405 ||| NNS
and  ||| S:1405 E:1409 ||| CC
populations ||| S:1409 E:1420 ||| NNS
) ||| S:1420 E:1421 ||| -RRB-
.  ||| S:1421 E:1423 ||| .
The  ||| S:1423 E:1427 ||| DT
promising  ||| S:1427 E:1437 ||| JJ
approach  ||| S:1437 E:1446 ||| NN
for  ||| S:1446 E:1450 ||| IN
assessing  ||| S:1450 E:1460 ||| VBG
the  ||| S:1460 E:1464 ||| DT
functional  ||| S:1464 E:1475 ||| JJ
efficacy  ||| S:1475 E:1484 ||| NN
of  ||| S:1484 E:1487 ||| IN
FF  ||| S:1487 E:1490 ||| NNP
is  ||| S:1490 E:1493 ||| VBZ
the  ||| S:1493 E:1497 ||| DT
concept  ||| S:1497 E:1505 ||| NN
of  ||| S:1505 E:1508 ||| IN
nutrigenomics ||| S:1508 E:1521 ||| NN
.  ||| S:1521 E:1523 ||| .
It  ||| S:1523 E:1526 ||| PRP
examines  ||| S:1526 E:1535 ||| VBZ
the  ||| S:1535 E:1539 ||| DT
link  ||| S:1539 E:1544 ||| NN
between  ||| S:1544 E:1552 ||| IN
the  ||| S:1552 E:1556 ||| DT
human  ||| S:1556 E:1562 ||| JJ
diet  ||| S:1562 E:1567 ||| NN
and  ||| S:1567 E:1571 ||| CC
the  ||| S:1571 E:1575 ||| DT
characteristics  ||| S:1575 E:1591 ||| NN
of  ||| S:1591 E:1594 ||| IN
his  ||| S:1594 E:1598 ||| PRP$
genome  ||| S:1598 E:1605 ||| NN
to  ||| S:1605 E:1608 ||| TO
determine  ||| S:1608 E:1618 ||| VB
the  ||| S:1618 E:1622 ||| DT
influence  ||| S:1622 E:1632 ||| NN
of  ||| S:1632 E:1635 ||| IN
food  ||| S:1635 E:1640 ||| NN
on  ||| S:1640 E:1643 ||| IN
the  ||| S:1643 E:1647 ||| DT
expression  ||| S:1647 E:1658 ||| NN
of  ||| S:1658 E:1661 ||| IN
genes  ||| S:1661 E:1667 ||| NNS
and ||| S:1667 E:1670 ||| CC
,  ||| S:1670 E:1672 ||| ,
ultimately ||| S:1672 E:1682 ||| RB
,  ||| S:1682 E:1684 ||| ,
to  ||| S:1684 E:1687 ||| TO
human  ||| S:1687 E:1693 ||| JJ
health ||| S:1693 E:1699 ||| NN
.  ||| S:1699 E:1701 ||| .
Nutrigenomic  ||| S:1701 E:1714 ||| JJ
approaches  ||| S:1714 E:1725 ||| NNS
are  ||| S:1725 E:1729 ||| VBP
promising  ||| S:1729 E:1739 ||| VBG
to  ||| S:1739 E:1742 ||| TO
assess  ||| S:1742 E:1749 ||| VB
the  ||| S:1749 E:1753 ||| DT
impact  ||| S:1753 E:1760 ||| NN
of  ||| S:1760 E:1763 ||| IN
probiotics  ||| S:1763 E:1774 ||| NN
in  ||| S:1774 E:1777 ||| IN
healthy  ||| S:1777 E:1785 ||| JJ
people ||| S:1785 E:1791 ||| NNS
.  ||| S:1791 E:1793 ||| .
The  ||| S:1793 E:1797 ||| DT
focusing  ||| S:1797 E:1806 ||| VBG
on  ||| S:1806 E:1809 ||| IN
the  ||| S:1809 E:1813 ||| DT
nutrigenomic  ||| S:1813 E:1826 ||| JJ
response  ||| S:1826 E:1835 ||| NN
of  ||| S:1835 E:1838 ||| IN
intestinal  ||| S:1838 E:1849 ||| JJ
microbial  ||| S:1849 E:1859 ||| JJ
community  ||| S:1859 E:1869 ||| NN
and  ||| S:1869 E:1873 ||| CC
its  ||| S:1873 E:1877 ||| PRP$
individual  ||| S:1877 E:1888 ||| JJ
populations  ||| S:1888 E:1900 ||| NNS
( ||| S:1900 E:1901 ||| -LRB-
in  ||| S:1901 E:1904 ||| IN
this  ||| S:1904 E:1909 ||| DT
regard  ||| S:1909 E:1916 ||| NN
the  ||| S:1916 E:1920 ||| DT
lactobacilli  ||| S:1920 E:1933 ||| NN
can  ||| S:1933 E:1937 ||| MD
be  ||| S:1937 E:1940 ||| VB
very  ||| S:1940 E:1945 ||| RB
informative ||| S:1945 E:1956 ||| JJ
)  ||| S:1956 E:1958 ||| -RRB-
was  ||| S:1958 E:1962 ||| VBD
proposed ||| S:1962 E:1970 ||| VBN
.  ||| S:1970 E:1972 ||| .
